Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is set to announce its earnings results after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, August 9th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 30.34% and a negative net margin of 12,536.05%. On average, analysts expect Aurinia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:AUPH opened at $5.65 on Tuesday. The firm has a market cap of $480.37 million, a P/E ratio of -6.14 and a beta of 2.22. Aurinia Pharmaceuticals has a 1-year low of $4.41 and a 1-year high of $6.69.

Several research analysts recently weighed in on the company. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 15th. BidaskClub lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 12th. Cantor Fitzgerald set a $18.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 1st. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, September 26th. Finally, ValuEngine raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $11.79.

TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: Find a Trading Strategy That Works

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply